MRI-guided optimisation of neoadjuvant chemotherapy duration in stage II–III HER2-positive breast cancer (TRAIN-3): a multicentre, single-arm, phase 2 study
2024 · The Lancet Oncology · 36 citations
https://doi.org/10.1016/s1470-2045(24)00104-9
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
17
Papers
389
Citations
10
h-index
10
i10-index
Grietje Bouma is an academic researcher. The author has contributed to research in topics: Neuroendocrine Tumor Research Advances & Lung Cancer Research Studies & Cancer survivorship and care. The author has an h-index of 10, co-authored 15 publications.
https://doi.org/10.1016/s1470-2045(24)00104-9
https://doi.org/10.1007/s00262-020-02556-1
Click to start Chat